Skip to main content
Journal of Antimicrobial Chemotherapy logoLink to Journal of Antimicrobial Chemotherapy
. 2024 Jun 3;79(7):1637–1644. doi: 10.1093/jac/dkae159

Evaluation of environmental antibiotic contamination by surface wipe sampling in a large care centre

Paul Sessink 1,, Birgit Tans 2, David Devolder 3, Rik Schrijvers 4,5, Isabel Spriet 6,7
PMCID: PMC11215530  PMID: 38828950

Abstract

Objectives

Exposure of healthcare workers to antibiotics may cause adverse health effects. Results of environmental contamination with antibiotics, obtained by taking surface wipe samples, can be used as an indicator for potential exposure to these sensitizing drugs. The objective was to describe the results of repeated measurements of contamination with antibiotics on multiple surfaces in hospital wards. Standardized needle and syringe preparation techniques and cleaning procedures were used.

Methods

The preparation table and the floor around the waste bin in six wards were sampled and analysed for contamination with the antibiotics amoxicillin, benzylpenicillin, cefotaxime, ceftriaxone, flucloxacillin, meropenem, piperacillin and vancomycin. Sampling was performed in four trials during 8 months. Depending on the outcome of the trials, the cleaning procedure was adapted. Liquid chromatography with tandem mass spectrometry was used for the analysis of the drugs.

Results

During the four trials, contamination with all eight antibiotics was omnipresent on all preparation tables and floors in the six wards. The highest contamination was found for amoxicillin (1291 ng/cm2). Changing the cleaning procedure did not reduce the level of contamination.

Conclusions

Surface contamination with the antibiotics was widespread and most probably caused by spillage during the preparation in combination with an ineffective cleaning procedure. Strategies should be developed and implemented by institutions for safe handling of antibiotics to reduce environmental contamination and potential exposure of healthcare workers to these sensitizing drugs.

Introduction

Antibiotics are widespread used in hospitals and many healthcare workers, especially nurses and pharmacy technicians, are preparing and administering these drugs daily. Although side effects of antibiotics in patients are well described, little is known about the adverse health effects in healthcare workers occupationally exposed to antibiotics.1 Reported effects include acute adverse drug reactions such as hypersensitivity, allergic skin reactions, respiratory symptoms and, although very rarely, anaphylactic shock, but antimicrobial resistance associated with long-term exposure has also been observed.2–6

Regulatory agencies have outlined the risks of handling sensitizing drugs and the importance to avoid cross-contamination, especially for penicillin and β-lactam antibiotics.7 To avoid the risk of cross-contamination, EU and FDA guidance indicate that (β-lactam) antibiotics should be manufactured in dedicated facilities.8,9 Reducing environmental contamination from antibiotics (e.g. in air) is also mentioned in the Global Action Plan on Antimicrobial Resistance, published by the World Health Organization in 2015. Environmental contamination is recognized as contributing to the emergence of antimicrobial resistance.10 However, no specific protocols exist for handling antibiotics by healthcare workers in hospitals. Mostly, only a hospital protocol for the preparation and administration is available and typically only gloves and/or a face mask are recommended as personal protective equipment (PPE).

Few studies have been published on occupational exposure of healthcare workers to antibiotics. A Swedish study has shown contamination of 12 antibiotics across 21 wards in 16 hospitals.11 A recent study in three European hospitals has shown widespread contamination with antibiotics on surfaces and in ambient air where nurses are preparing and administrating antibiotics.12 The nurses have also reported smelling the antibiotics, indicating they have been exposed.12

The objective of this study was to measure antibiotic surface contamination at different locations in six wards of the University Hospitals Leuven in Belgium. Over an 8 month period, monitoring was repeated four times to get a broader and more longitudinal picture of the contamination than with a single measurement. It was also evaluated whether adjusted cleaning procedures had an impact on the antibiotic contamination.

Materials and methods

Study design and site

The study was set up as a prospective observational study, and performed between 26 April and 31 December 2021, in the University Hospitals Leuven, Belgium, a 1950-bed academic tertiary care centre. Over the 8 month period, surface wipe sampling was repeated four times, to get a longitudinal insight in antibiotic surface contamination. Besides, cleaning procedures were adjusted the period before each measurement, to evaluate potential impact on the contamination levels. Ethical approval was not applicable as there was no involvement of patients and nurses.

At the University Hospitals Leuven, antimicrobial stewardship is carried out based on a multifaceted approach. Antimicrobial guidelines including information on reconstitution, dilution and administration of antibiotics, are updated regularly and can be accessed via a locally hosted platform.13

Selection of antibiotics and wards

Contamination with the antibiotics amoxicillin(-clavulanic acid), benzylpenicillin, cefotaxime, ceftriaxone, flucloxacillin, meropenem, piperacillin(-tazobactam), and vancomycin was measured by surface wipe sampling at six hospital wards.

The wards evaluated were a paediatric oncology/haematology ward (20 beds), an adult haematology ward (15 beds), pulmonology (28 beds), a surgical intensive care unit (17 beds), general internal medicine (28 beds) and orthopaedics (28 beds). These wards were selected as they represent wards with a high frequency of patients suffering from infections, e.g. neutropenic fever, bacteraemia, pneumonia, urinary tract infections, osteomyelitis, fracture-related infections and prosthesis-related infections. Consequently, antibiotic treatment is carried out very frequently at these wards.

An overview of the total number of antibiotic vials processed by the nurses per ward on an annual basis is presented in Table 1. When standard dosing in (adult) patients with a normal kidney function is applied, nurses handle one vial (for ceftriaxone 2 g), two vials (for vancomycin 1 g), three vials (for meropenem 1 g and for cefotaxime 2 g) or at least four vials (for piperacillin-tazobactam 4 g, for amoxicillin 1 g, for flucloxacillin 1 g and for benzylpenicillin 1–2 MIU) daily.

Table 1.

Mean annual numbers of antibiotic vials used in the wards (2019–2021)

Ward Vancomycin Cefotaxime Ceftriaxone Benzylpenicillin Amoxicillin Meropenem Piperacillin Flucloxacillin All eight antibiotics
A: Paediatric oncology/haematology 4256 330 51 27 456 3184 354 158 8816
B: Adult haematology 3588 64 125 9 1560 2596 1728 488 10 158
C: Pulmonology 4672 49 96 0 1869 4395 4270 574 15 925
D: Intensive care unit 5330 538 136 105 2512 3612 4889 846 17 968
E: General internal medicine 1741 293 435 866 2245 1110 2493 2156 11 339
F: Orthopaedics 690 16 18 13 487 28 638 314 2204
All six wards 20 277 1290 861 1020 9129 14 925 14 372 4536 66 410

The antibiotics are prepared by the nurses using needle and syringe technique on the tables being sampled. All antibiotics monitored are dispensed as lyophilized powder in vials. First, the powder is reconstituted with 10 or 20 mL of water for injection or normal saline. Second, depending on the specific antibiotic, the concentrated antibiotic solution is further diluted with normal saline to 50 mL (for syringes at the intensive care unit) or 100–250 mL infusion bags (for the other wards), followed by administration to the patient. For this study, the nurses wore standard (no additional) working clothes and used only gloves as PPE.

Sampling surfaces, sampling schedule and cleaning procedures

Two identical surfaces were monitored at each ward, i.e. the preparation table (High Pressure Laminate) and floor (Linoleum) around the waste bin in which empty vials were discarded (Table 2). The wipe samples were obtained using AB Wipe Kits from Exposure Control Sweden AB.14 The kits contained materials (paper tissues, droppers with distilled water, containers for sample storage and gloves for personal protection) to take wipe samples from several types of surface.

Table 2.

Surface contamination with eight antibiotics in six wards during four trials (ng/cm2)

Ward Description surface Surface
(cm2)
Vancomycin Cefotaxime Ceftriaxone Benzylpenicillin Amoxicillin Meropenem Piperacillin Flucloxacillin
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
A: Paediatric oncology/haematology Preparation table 900 2.45 1.55 155 1.14 ND ND ND 973 ND ND ND ND ND ND ND ND ND ND 0.18 ND 19 293 0.31 0.09 0.03 ND 44 ND ND ND ND ND
Floor around waste bin 900 4.36 1.28 299 96 0.07 0.10 0.14 49 ND ND ND ND ND ND ND ND ND ND 20 0.33 1.83 2.32 1.48 3.06 0.15 0.20 1.61 0.05 0.01 0.01 2.53 0.15
B: Adult haematology Preparation table 1054 1.13 0.14 14 4.56 ND ND ND 0.04 0.04 ND ND ND ND ND ND ND 14 6.24 ND 0.74 0.07 0.03 0.74 0.07 12 12 0.31 10 ND ND ND 16
Floor Around waste bin 900 1.79 0.70 16 3.16 ND ND ND 0.06 0.04 ND 0.11 ND ND ND ND ND 122 3.40 ND 44 74 1.64 3.13 44 159 47 1.27 44 0.62 0.12 ND 194
C: Pulmonology Preparation table 3500 2.63 2.63 1.17 0.24 ND ND ND 0.01 0.09 0.11 ND ND ND ND ND ND 5.43 1.52 0.07 0.06 0.39 0.21 0.03 0.01 1.08 0.85 0.42 0.55 0.01 0.01 0.01 0.02
Floor around waste bin 900 0.26 0.21 0.19 0.30 ND ND ND 0.03 0.04 ND ND ND ND ND ND ND 347 101 0.43 0.93 7.36 3.70 ND 0.04 26 18 0.81 2.92 0.19 0.09 0.03 0.02
D: Intensive care unit Preparation table 500 0.53 0.26 16 68 ND ND 1.25 ND ND ND ND ND ND ND ND ND 0.05 ND 0.33 0.03 0.38 0.15 0.20 0.66 0.12 0.11 0.40 0.12 0.03 ND ND 12
Floor around waste bin 500 4.63 1.52 7.26 1.25 0.03 ND 0.41 ND 0.11 0.06 0.25 ND ND ND ND ND 1.04 0.38 0.81 ND 2.70 0.80 0.23 1.27 1.75 1.47 0.57 0.24 ND ND ND 0.69
E: General internal medicine Preparation table 500 0.74 3.41 2.97 1.53 0.51 ND 0.65 53 0.11 ND 1.51 ND ND 5.73 1.94 665 9.16 2.61 9.76 40 0.09 0.03 0.74 0.04 26 22 21 8.15 9.60 0.13 11 1.21
Floor around waste bin 500 ND 1.49 12 4.68 ND ND ND 22 ND ND 0.09 53 ND 2.80 0.13 119 ND 0.75 7.59 1291 ND ND 0.56 0.90 0.07 26 0.89 1178 0.30 1.13 3.28 0.25
F: Orthopaedics Preparation table 500 8.12 0.24 45 22 ND 0.21 ND ND ND 0.11 ND 8.98 63 ND ND 0.50 17 2.44 4.34 0.30 0.04 0.04 0.52 2.66 16 15 0.53 8.73 0.37 7.95 30 0.31
Floor around waste bin 500 14 0.14 14 191 ND ND ND ND 0.05 ND ND 0.37 59 ND ND 21 7.23 0.09 1.14 0.36 ND ND 0.22 0.53 140 57 4.86 158 5.20 1.05 115 0.56

ND, not detected.

As shown in Figure 1, wipe samples were taken between 7.30 and 8.30 in the morning before start of the shift (trial 1), and in the afternoon between 16.00 and 17.30 at the end of the shift before cleaning (trial 2). Wipe sampling before cleaning at the end of the shift was repeated 3 months later (trial 3) and 8 months later (trial 4). Per standard protocol, the tables were cleaned with 1% Incidin® Plus while PolGreen Odor Line Indoors was used to clean the floors.15,16 After trial 2, preparation protocols and procedures were not changed but cleaning was performed more frequently during the shift using an alkaline diluted household cleaning product (Dreft Original, Procter & Gamble, Belgium), combining alkaline and surface-active characteristics. After trial 3, additional extensive cleaning under supervision of pharmacy staff was performed using the same alkaline detergent, followed by 70% alcohol. The additional cleaning was only performed on the preparation tables, not on the floors.

Figure 1.

Figure 1.

Overview of the study set-up presenting the trials 1–4 at three timepoints, including adjustments in cleaning procedures. aStandard cleaning was carried out with 1% Incidin® Plus (tables) and PolGreen Odor Line Indoors (floors). bCleaning with Dreft Original. cCleaning with Dreft Original followed by 70% alcohol.

Surface wipe sampling, storage, transport and sample preparation

The wipe samples were taken by or under the supervision of an experienced hospital pharmacist. The dimensions of the surfaces were measured and the areas calculated. All samples were stored at −20°C after sampling, during transport and at the laboratory until sample preparation and analysis. The wipe samples were prepared for analysis by adding distilled water. Total extraction volume was 100 mL. After extraction, a part of the extract was used for analysis. The antibiotics were analysed with liquid chromatography and tandem mass spectrometry, as described next. Finally, the contamination in ng per cm2 was calculated, a common expression in surface wipe sampling to compare the level of contamination between the surfaces within the study and between published studies. In addition, the contamination score was calculated. The score was 100% if all eight antibiotics were detected on all 12 surfaces during the four trials (8 drugs multiplied with 12 surfaces multiplied by 4 trials gains 384 outcomes).

Liquid chromatography with tandem mass spectrometry analysis

Analysis was performed on a Xevo TQ-S micro mass spectrometer combined with an Acquity UPLC H-class sample manager and quaternary solvent manager controlled by Masslynx software (Waters, Milford, USA). An Acquity BEH C18, 1.7 µm, 2.1 × 100 mm separation column (Waters, Milford, USA) operated at 40°C was used.

Elution (0.35 mL/min) started with a composition of 100% solvent A (100% MilliQ RO-water with 0.1% formic acid) and 0% solvent B (100% acetonitrile with 0.1% formic acid) with a delay of 2 minutes. Between 2 and 7 minutes, the composition changed to 100% B and from 7.5 minutes starting conditions were restored. Total runtime was 11 minutes, and the injection volume was 8 µL. The mass spectrometer was operated with a capillary voltage of +3 KV, a desolvation temperature of 500°C and a nitrogen flow of 1100 L/hour. Cone gas flow was set at 50 L/min (nitrogen). Argon was used as collision gas. All transitions were measured in positive mode. The antibiotics had a linear calibration curve up to 100 ng/mL. The detection limit was 0.1 ng/mL for amoxicillin and flucloxacillin, and 0.15 ng/mL for the other antibiotics.

Results

The overall results of the four trials show total spread of contamination with antibiotics up until 1291 ng/cm2 (Table 2). Two hundred and fifty-three out of 384 possible outcomes were positive indicating a contamination score of 66%. Contamination scores per ward for each of the trials are presented in Table 3 indicating some differences between the wards and between the trials.

Table 3.

Contamination score per ward for the four trials (%)

Ward Trial 1 Trial 2 Trial 3 Trial 4 All four trials
A: Paediatric oncology/haematology 50 44 63 56 53
B: Adult haematology 69 56 44 75 61
C: Pulmonology 75 69 56 75 69
D: Intensive care unit 69 50 69 56 61
E: General internal medicine 56 69 94 94 78
F: Orthopaedics 75 69 63 88 73
All six wards 66 59 65 74 66

For both trials 1 and 2, all surfaces were contaminated with two to seven antibiotics indicating total spread of contamination of the antibiotics at the six wards. Piperacillin and vancomycin were found on all surfaces followed by meropenem, amoxicillin and flucloxacillin. Cefotaxime, ceftriaxone and benzylpenicillin were observed less frequently, and mostly in a few wards. The highest contamination was observed for piperacillin, amoxicillin and meropenem, followed by benzylpenicillin, vancomycin and flucloxacillin. The lowest contamination was found for cefotaxime and ceftriaxone. Considering the overall contamination totalling the concentrations of all eight antibiotics on preparation tables and floors, the median contamination can be ranked as follows: ward E > ward F > ward C > ward B > ward D > ward A. In general, the contamination is comparable in both trials.

For trial 3, all surfaces were contaminated with three to eight antibiotics indicating total spread of contamination on the six wards. Piperacillin and vancomycin were found on all surfaces followed by meropenem, amoxicillin and flucloxacillin. Cefotaxime, ceftriaxone and benzylpenicillin were observed less frequently, and mostly in a few wards. The highest contamination was observed for vancomycin, flucloxacillin, piperacillin and amoxicillin followed by meropenem. The lowest contamination was found for cefotaxime, ceftriaxone and benzylpenicillin. Considering the total contamination of the eight antibiotics on preparation tables and floors, the median contamination can be ranked as follows: ward E > ward F > ward D > ward A > ward C > ward B. In general, the contamination has increased for vancomycin, amoxicillin, meropenem and flucloxacillin in trial 3 compared to trial 2. The contamination has decreased for piperacillin, and was unchanged for cefotaxime, ceftriaxone and benzylpenicillin. Increase of contamination in trial 3 compared to trial 2 was observed for wards A, D, E and F. A decrease was observed in ward C, while no changes were found in ward B.

For trial 4, all surfaces were contaminated with three to eight antibiotics indicating total spread of contamination on the six wards. Meropenem and vancomycin were found on all surfaces followed by piperacillin, flucloxacillin, amoxicillin and cefotaxime. Benzylpenicillin and ceftriaxone were observed less frequently, and only on wards E and F. The highest contamination was observed for vancomycin, and cefotaxime on four surfaces, for benzylpenicillin, flucloxacillin, piperacillin and amoxicillin on three surfaces, and for ceftriaxone and meropenem on one surface. Considering the total contamination of the eight antibiotics on preparation tables and floors, the median contamination can be ranked as follows: ward E > ward B > ward F > ward A > ward D > ward C. In general, the contamination increased for cefotaxime, meropenem, piperacillin and flucloxacillin in trial 4 compared to trial 3. The contamination decreased for vancomycin, and amoxicillin, and was unchanged for ceftriaxone, and benzylpenicillin. However, it should be noted that this was not the case for vancomycin at ward F, for benzylpenicillin, ceftriaxone and amoxicillin at ward E and for amoxicillin at ward B. These exceptions show a substantial increase of the contamination compared to trial 3. In general, an increase of the contamination in trial 4 compared to trial 3 was observed for the wards B, and E. A decrease was observed for the wards A, and D whereas no changes were found for the wards C, and F.

Discussion and conclusions

In this study, evaluating environmental contamination with antibiotics on a large scale in a university hospital setting, it is shown that contamination with up to eight antibiotics is widespread with high levels of contamination on the preparation tables and on the floors, located next to waste bins. Cleaning appeared to be ineffective as already in trial 1, before start of the shift, substantial and widespread contamination was found. Contamination continues, also in trial 3, when more frequent cleaning with an alkaline and surface-active detergent was performed during the shift. Therefore, additional extensive cleaning was performed under the supervision of the pharmacy staff before trial 4 was conducted. However, the contamination was not reduced and seems to be persistent and difficult to remove once present.

It is obvious that the contamination is caused by the preparation technique. The use of the needle and syringe technique for reconstitution of the lyophilized powder and subsequent dilution in the infusion fluid has resulted in spillage due to overpressure in the drug vials and during withdrawal of the needle-syringe from the vials. In addition, spiking of infusion bags might also cause spillage. Consequently, the preparation area (table and floor around the waste bin) gets contaminated. However, additional contamination from (the exterior of the) drug vials cannot be excluded.17,18 Vials were not checked for contamination on the outside and it is possible that contamination on the vials has been transferred e.g. by hands or gloves to other surfaces including the preparation tables.

As far as we know, two studies have been published measuring surface contamination with antibiotics. A Swedish study has shown contamination of 12 antibiotics across 21 wards in 16 hospitals.11 Half of the wards had contamination levels >0.5 ng/cm2. The lowest contamination was observed for the wards using a closed-system drug-transfer device (CSTD). In the other study three European hospitals were involved.12 Widespread contamination with seven antibiotics up to 767 ng/cm2 was found in the wards. After CSTD implementation, contamination levels were significantly decreased.

According to the National Institute for Occupational Safety and Health, a CSTD is defined as a drug-transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of the hazardous drug or vapour concentrations outside the system.19 USP <800> recommends the use of CSTDs for hazardous drug compounding but CSTDs are required during hazardous drug administration.20 As CSTDs offer enhanced protection to healthcare workers, they are routinely used, also in our centre, for compounding and administration of hazardous drugs, in combination with other protective measures such as biohazard cabinets and PPE.21–27 It is expected that the contamination with antibiotics found in the present study will also be reduced after implementation of a CSTD. It is obvious that hospital wide implementation of a CSTD for antibiotics will have a major financial impact as antibiotics are estimated to be used in one-third of the hospitalized patients.28

The surface wipe sample results clearly show high levels of environmental contamination with antibiotics and, hence, it is expected that contaminated surfaces might result in exposure of the healthcare workers. An overview of studies published between 2000 and 2023 evaluating whether exposure might lead to adverse health effects in healthcare workers is presented in Tables 4 and 5. Both immediate and delayed-type hypersensitivity reactions after occupational exposure have been described. In case of type I (IgE-mediated) sensitization, contact urticaria up to anaphylaxis, even after airborne exposure, have been described. In case of a type IV (T-cell mediated) sensitization pattern, the clinical presentation was mostly occupational allergic contact dermatitis (OACD) affecting the hands and to a lesser extent forearms or face, the last indicating airborne dermatitis. Sensitization was not always accompanied by symptoms, and it remains unknown to what extent systemic exposure would induce reactions in the evaluated healthcare workers.2,3,37 The prevalence of penicillin sensitization in these studies decreased, paralleling a decrease in use.2,31 The sensitization rate to the evaluated antibiotics in our study remains unknown. Recent work suggested a sensitization rate of only 1% for antibiotic-induced OACD among referred healthcare workers,29 although studies systematically evaluating all healthcare workers reported sensitization rates from 0.7 up to 12% (2.6%–12% for type I and 0.7%–9.8% for type IV).2,3,31,37 It is less clear, and difficult to investigate, what the impact is of long-term exposure to broad-spectrum antimicrobials on e.g. the development of antimicrobial resistance of the skin microbiome. Ideally, both types of exposure should be avoided by healthcare workers.

Table 4.

OACD to antibiotics reported in literature

Author (year), country Population (n) Testing procedure Results Remarks
Gilissen et al. (2019), Belgium29 HCWs (n = 201)
201 OACD patients out of 1248 HCWs examined 2001–2019.
Patch 26/201 (13%) had OACD to systemic drug(s), 3 (1%) for antibiotics (2 BL). Hands were mostly affected, but also face (airborne dermatitis) was observed.
Pinheiro et al. (2018), Portugal4 HCWs (n = 4)
Monocentric, retrospective description of OACD to systemic antibiotics in HCWs, 2010–2016.
Patch 4 cases with OACD to cephalosporins (3) and/or penicillins (2).
One patient with pre-existing DRESS after (systemic exposure to) flucloxacillin.
Hands (mainly dorsa), forearms and face were affected. Generalized rash on airborne exposure was observed.
Yesudian and King (2001), UK30 HCW (n = 1)
Case report.
Patch OACD (face) due to meropenem.
Rudzki et al. (1999), Poland31 HCW (not reported)
Monocentric, retrospective data of percentage positive penicillin patch tests among nurses, 1971–1998.
Patch Sensitization rate among nurses with OACD was 0.7% to 9.8%. A decreasing trend in sensitization rate from 1990 onwards was observed.
Foti et al. (1997), Italy32 HCW (n = 18)
Monocentric case series with OACD with exposure to cephalosporins (nurses).
Patch, SPT, IDT 8/18 (44%) showed positive patch testing. Hands (18 cases), forearms (3 cases), face (2 cases) were affected.

HCW, healthcare worker; BL, ß-lactams; DRESS, drug reaction with eosinophilia and systemic symptoms; SPT, skin prick testing; IDT, intradermal skin testing.

Table 5.

Occupational IgE-mediated allergy to systemically used antibiotics

Author (year), country Population (n) Testing procedure Results Remarks
Gaspar-Marques et al. (2018), Portugal33 HCW (n = 1)
Case report, nurse.
SPT, IDT Recurrent anaphylaxis at work and after piperacillin-tazobactam preparation with positive skin tests for penicillins, cefuroxime. Airborne exposure-induced anaphylaxis.
Merget et al. (2017), Germany34 HCW (n = 1)
Case report, nurse.
SPT, IDT, sIgE, BAT, inhalation provocation Recurrent anaphylaxis; severe anaphylaxis after oral cefuroxime exposure. Inhalation of 10 μg cefuroxime induced generalized urticaria.
Classen and Fuchs (2015), Germany35 HCW (n = 1)
Case report, nurse.
SPT, IDT, open Patch, rub test Recurrent contact urticaria when preparing BL antibiotics.
Kim et al. (2012), South Korea3 HCW (n = 161)
Recruitment from a single tertiary centre.
SPT to cefotiam, ceftriaxone, ceftizoxime Sensitization rate was 3.1%. Also sIgE determination was performed showing a 17.4% sensitization prevalence (but relevance is debatable).
Also 86 non-atopic non-allergic controls included but without data on SPT results.
Kim et al. (2011), South Korea36 HWC (n = 1)
Case report, nurse.
sIgE testing Anaphylaxis after administration of piperacillin-tazobactam. Pre-existing atopic dermatitis.
Choi et al. (2010), South Korea37 HCW (n = 311)
457 out of 539 staff nurses at a tertiary centre responded to a questionnaire, 318 received skin testing, 311 were analysed.
SPT (cefotiam, cefoperazone, ceftizoxime, flomoxef, piperacillin, penicillin G Sensitization rate was 2.6% (8 out of 311).
Symptoms of contact urticaria were present in 5/8 HCWs.
In 7/8 for at least one penicillin, 6/8 for at least one cephalosporin.
Sensitization was more prevalent in those with versus without a pre-existing skin disorders (atopic dermatitis, urticaria, contact dermatitis) (6.9% versus 1.3%, P = 0.018).
Cetinkaya et al. (2007), Turkey2 HCWs (n = 83)
Nurses handling beta-lactam antibiotics.
SPT, IDT (PPL, MDM) 10 (12%) had positive skin tests. None had reacted but limited/no exposure. Interpreted as occult sensitization.

HCW, healthcare worker; SPT, skin prick testing; IDT, intradermal skin testing; sIgE, specific IgE; BAT, basophil activation test; PPL, penicilloyl polylysine; MDM, minor determinant mixture.

Currently there are no recommendations for safe handling, cleaning or risk assessment for surface contamination with antibiotics. Determination of contamination at individual facilities via regular monitoring programmes as performed in this study may identify potential exposure of healthcare workers and patients to these harmful drugs. Update of cleaning procedures, including alternative or additional cleaning agents, may reduce the antibiotic surface contamination but requires assessment of its effectiveness as performed for hazardous drugs.38 Ultimately, implementation of engineering controls such as CSTDs or similar devices may provide the most effective method to reduce or eliminate the environmental contamination and the exposure risk. As no specific official regulations for antibiotics exist, it is recommended that legal authorities and professional organizations of hospital pharmacists and nurses take the initiative to develop these to ensure safety of the healthcare workers. The European Centre for Disease Prevention and Control and the European Society of Clinical Microbiology and Infectious Diseases could be other relevant stakeholders in this process.

The main limitation of our study concerns the uncertainty to determine the actual levels of contamination for the antibiotics on the different surfaces. The main issue is the wipe efficiency depending on type of surface, liquid, paper tissue and the chemical and physical characteristics of the antibiotics. A single wipe test as performed will not be able to remove all residual surface contamination especially when it concerns rough and sticky surfaces. Only smooth surfaces such as plastics and stainless steel will give high recoveries and reliable results. Recovery and wipe efficiency have been validated for seven antibiotics on plastic and stainless steel and ranged from 21% for piperacillin to 94% for cefotaxime.12 The solubility of the antibiotics in water is high and consequently the extraction from the tissue is very efficient. As there are many variables involved, it is impossible to determine the exact recovery for each antibiotic on all types of surface. Hence, the results presented are not corrected for recovery. Consequently, the actual surface contamination will be higher than the measured contamination.

Other limitations are the absence of statistical analysis, assessment of stability of antibiotics during storage of wipes and lack of reference values for surface contamination. Statistical analysis is lacking as we decided to perform a descriptive study based on four trials. The focus was to explore antibiotic contamination hospital wide and not to look for differences between wards, antibiotics and surfaces monitored. Potential degradation of the antibiotics, e.g. meropenem, during storage of the wipes in the freezer was not monitored.39 Currently, there are no upper limit thresholds for antibiotic surface contamination based on a risk assessment related to adverse health effects. Lacking reference values makes interpretation of the contamination levels difficult. When compared to previous measurements for hazardous drugs, antibiotic contamination levels are markedly higher, probably related to the fact that antibiotic doses are typically from 100- up to 1000-fold higher compared to hazardous drugs.27 As antibiotics are considered sensitizing drugs, the precautionary principle should be applied, i.e. exposure should be minimized as much as possible.

In conclusion, surface contamination with antibiotics is probably caused by spillage during preparation in combination with an ineffective cleaning procedure. The widespread contamination requires attention to avoid potential adverse health effects for healthcare workers. Future research should focus on the impact of CSTD implementation and effective cleaning procedures.

Acknowledgements

The authors thank the University Hospitals Leuven, Belgium for the collaboration to perform this study. Parts of the study were poster presented at the 27th Congress of the European Association of Hospital Pharmacists in Lisbon from 22 to 24 March 2023 and at the European Conference of Oncology Pharmacy ECOP 5 in Hamburg from 30 June to 2 July 2022.

Contributor Information

Paul Sessink, Exposure Control Sweden AB, Bohus-Björkö, Sweden.

Birgit Tans, Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

David Devolder, Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

Rik Schrijvers, Department of Microbiology, Immunology, and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium; Department General Internal Medicine-Allergy and Clinical Immunology, University Hospitals Leuven, Leuven, Belgium.

Isabel Spriet, Pharmacy Department, University Hospitals Leuven, Leuven, Belgium; Department of Pharmaceutical and Pharmacological Sciences, University Leuven, Leuven, Belgium.

Funding

Financial support for this study (research, authorship, and publication) was provided by ICU Medical, Inc., San Clemente, USA. R.S. is supported by a senior clinical investigator fellowship by the National Fund for Scientific Research (FWO, 1805523N).

Transparency declarations

P.S., B.T., D.D. and I.S. designed the study. P.S. and I.S. collected the data. P.S. performed the analysis and interpreted the results. P.S. drafted the manuscript. All authors reviewed and approved the final version of the manuscript.

References

  • 1. Centers for Disease Control and Prevention . Antibiotic Use in the United States, 2021 Update: Progress and Opportunities. US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/antibiotic-use/pdfs/stewardship-report-2021-H.pdf [Google Scholar]
  • 2. Cetinkaya  F, Ozturk  AO, Kutluk  G  et al.  Penicillin sensitivity among hospital nurses without a history of penicillin allergy. J Adv Nurs  2007; 58: 126–9. 10.1111/j.1365-2648.2006.04155.x [DOI] [PubMed] [Google Scholar]
  • 3. Kim  JE, Kim  SH, Jin  HJ  et al.  Ige sensitization to cephalosporins in health care workers. Allergy Asthma Immunol Res  2012; 4: 85–91. 10.4168/aair.2012.4.2.85 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Pinheiro  V, Pestana  C, Pinho  A  et al.  Occupational allergic contact dermatitis caused by antibiotics in healthcare workers—relationship with non-immediate drug eruptions. Contact Derm  2018; 78: 281–6. 10.1111/cod.12960 [DOI] [PubMed] [Google Scholar]
  • 5. Tadokoro  K, Niimi  N, Ohtoshi  T  et al.  Cefotiam-induced IgE-mediated occupational contact anaphylaxis of nurses; case report, RAST analysis, and a review of the literature. Clin Exp Allergy  1994; 24: 127–33. 10.1111/j.1365-2222.1994.tb00208.x [DOI] [PubMed] [Google Scholar]
  • 6. Colagiovanni  A, Feliciani  C, Fania  L  et al.  Occupational contact dermatitis from carbapenems. Cutis  2015; 96: E1–3. [PubMed] [Google Scholar]
  • 7. Petrelli  F, Caraffa  A, Scuri  S  et al.  The requirements for manufacturing highly active or sensitising drugs comparing good manufacturing practices. Acta Biomed  2019; 90: 288–99. 10.23750/abm.v90i2.8340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. EudraLex . EU Guidelines to Good Manufacturing Practice for Medicinal Product for Human and Veterinary Use. Volume 4. Part 1. Chapter 3: Premises and equipment and Chapter 5: Production. 2008. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  • 9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research . Guidance for Industry. Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination. April 2013. https://www.fda.gov/files/drugs/published/Non-Penicillin-Beta-Lactam-Drugs–A-CGMP-Framework-for-Preventing-Cross-Contamination.pdf
  • 10. World Health Organization . Global Action Plan on Antimicrobial Resistance. 2016. https://www.who.int/publications/i/item/9789241509763 [DOI] [PubMed]
  • 11. Nygren  O, Lindahl  R. Screening of spill and leakage of antibiotics in hospital wards. J ASTM Int  2011; 8: 1–24. 10.1520/JAI103453 [DOI] [Google Scholar]
  • 12. Sessink  PJM, Nyulasi  T, Haraldsson  ELM  et al.  Reduction of contamination with antibiotics on surfaces and in environmental air in three European hospitals following implementation of a closed-system drug transfer device. Ann Work Expo Health  2019; 63: 459–67. 10.1093/annweh/wxz010 [DOI] [PubMed] [Google Scholar]
  • 13.www.antibioticagids.be
  • 14.www.exposurecontrol.net
  • 15.https://d213yzj61vi89h.cloudfront.net/Bunzl-GLO-Site/attachments/nl_BE/GLN/technique/T511602N.pdf
  • 16.https://en.pollet.eu/downloads/
  • 17. Fleury-Souverain  S, Nussbaumer  S, Mattiuzzo  M  et al.  Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. J Oncol Pharm Pract  2014; 20: 100–11. 10.1177/1078155213482683 [DOI] [PubMed] [Google Scholar]
  • 18. Power  LA, Sessink  PJM, Gesy  K  et al.  Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Hosp Pharm  2014; 49: 355–62. 10.1310/hpj4904-355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. National Institute for Occupational Safety and Health . NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and other Hazardous Drugs in Health Care Settings. 2004. Publication No. 2004-165. http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf
  • 20. United States Pharmacopoeia . General chapter <800> Hazardous Drugs—Handling in Healthcare Settings. 2017. https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare
  • 21. Yoshida  J, Tei  G, Mochizuki  C  et al.  Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg  2009; 53: 153–60. 10.1093/annhyg/men081 [DOI] [PubMed] [Google Scholar]
  • 22. Sessink  PJM, Connor  TH, Jorgenson  JA  et al.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract  2011; 17: 39–48. 10.1177/1078155210361431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Sessink  PJM, Trahan  J, Coyne  JW. Reduction in surface contamination with cyclophosphamide in 30 US hospital pharmacies following implementation of a closed-system drug transfer device. Hosp Pharm  2013; 48: 204–12. 10.1310/hpj4803-204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Simon  N, Vasseur  M, Pinturaud  M  et al.  Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug compounding unit: a prospective, controlled, parallel study. PLoS ONE  2016; 11: e0159052. 10.1371/journal.pone.0159052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Vyas  N, Turner  A, Clark  JM  et al.  Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator. J Oncol Pharm Pract  2016; 22: 10–9. 10.1177/1078155214544993 [DOI] [PubMed] [Google Scholar]
  • 26. Bishay  S, Michalowska-Suterska  M, Edling  A  et al.  Evaluation of the hazardous drug surface contamination in pharmacy compounding and administration clinical setting after adoption of standardized cleaning workflow and a closed system transfer device. Pharm Technol Hosp Pharm  2022; 7: 20220004. 10.1515/pthp-2022-0004 [DOI] [Google Scholar]
  • 27. Sessink  PJM, Tans  B, Spriet  I  et al.  Longitudinal evaluation of environmental contamination with hazardous drugs by surface wipe sampling. J Oncol Pharm Pract  2023. [Online ahead of print] 10.1177/10781552231205481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Vandael  E, Latour  K, Goossens  H  et al.  Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the global-PPS and ECDC-PPS 2017. Antimicrob Resist Infect Control  2020; 9: 13. 10.1186/s13756-019-0663-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Gilissen  L, Boeckxstaens  E, Geebelen  J  et al.  Occupational allergic contact dermatitis from systemic drugs. Contact Derm  2020; 82: 24–30. 10.1111/cod.13383 [DOI] [PubMed] [Google Scholar]
  • 30. Yesudian  PD, King  CM. Occupational allergic contact dermatitis from meropenem. Contact Derm  2001; 45: 53–53. 10.1034/j.1600-0536.2001.045001053.x [DOI] [PubMed] [Google Scholar]
  • 31. Rudzki  E, Rebandel  P, Hudymowicz  W. Decrease of frequency of occupational contact sensitivity to penicillin among nurses in Warsaw. Contact Derm  1999; 41: 114–114. 10.1111/j.1600-0536.1999.tb06247.x [DOI] [PubMed] [Google Scholar]
  • 32. Foti  C, Bonamonte  D, Trenti  R  et al.  Occupational contact allergy to cephalosporins. Contact Derm  1997; 36: 104–5. 10.1111/j.1600-0536.1997.tb00423.x [DOI] [PubMed] [Google Scholar]
  • 33. Gaspar-Marques  J, Finelli  E, Martins  PC  et al.  Piperacillin-tazobactam anaphylaxis: a rare cause of occupational disease. Eur Ann Allergy Clin Immunol  2018; 50: 89–91. 10.23822/EurAnnACI.1764-1489.29 [DOI] [PubMed] [Google Scholar]
  • 34. Merget  R, Sander  I, Fartasch  M  et al.  Occupational generalized urticaria and anaphylaxis after inhalation of cefuroxime in a nurse. Am J Ind Med  2018; 61: 261–6. 10.1002/ajim.22788 [DOI] [PubMed] [Google Scholar]
  • 35. Classen  A, Fuchs  T. Occupational allergy to β-lactam antibiotics. Allergo J Int  2015; 24: 54–7. 10.1007/s40629-015-0047-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Kim  JE, Kim  SH, Kim  JH  et al.  A case of piperacillin-induced occupational anaphylaxis: detection of serum IgE to piperacillin-HAS conjugate. J Korean Med Sci  2011; 26: 682–5. 10.3346/jkms.2011.26.5.682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Choi  IS, Han  ER, Lim  SW  et al.  Beta-lactam antibiotic sensitization and its relationship to allergic diseases in tertiary hospital nurses. Allergy Asthma Immunol Res  2010; 2: 114–22. 10.4168/aair.2010.2.2.114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Simon  N, Guichard  N, Odou  P  et al.  Efficiency of four solutions in removing 23 conventional antineoplastic drugs from contaminated surfaces. PLoS ONE  2020; 15: e0235131. 10.1371/journal.pone.0235131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Gijsen  M, Filtjens  B, Annaert  P  et al.  Meropenem stability in human plasma at -20°C: detailed assessment of degradation. Antibiotics  2021; 10: 449. 10.3390/antibiotics10040449 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Antimicrobial Chemotherapy are provided here courtesy of Oxford University Press

RESOURCES